Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215117 | 0.87 | HRH1 (0.49) | HRH1CCR3HRH3EPHX2 | |
| SCHEMBL216865 | 0.87 | CCR5 (0.44) | SRD5A1SRD5A2HRH3EPHX2 | |
| SCHEMBL12485444 | 0.87 | GPR119 (0.46) | SRD5A1SRD5A2HRH1CCR3HRH3 | |
| SCHEMBL6341704 | 0.87 | EPHX2 (0.42) | SRD5A1SRD5A2HRH1CCR3HRH3 | |
| SCHEMBL213590 | 0.84 | SRD5A1 (0.50) | SRD5A1SRD5A2HRH3SCD5EPHX2 | |
| SCHEMBL213412 | 0.83 | LMNA (0.45) | SRD5A1SRD5A2 | |
| SCHEMBL3292130 | 0.82 | OPRK1 (0.49) | SRD5A1HRH1CCR3OPRK1SCD5 | |
| SCHEMBL215797 | 0.81 | GPR119 (0.59) | HRH3 | |
| SCHEMBL15174208 | 0.80 | F10 (0.39) | SRD5A1HRH3 | |
| SCHEMBL25186260 | 0.79 | HRH3 (0.49) | SRD5A1HRH1CCR3HRH3SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | SRD5A1 4714/4885SRD5A2 3895/4885HRH1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.